We have also shown that this antiapoptotic phenotype can be overcome in CML by targeting BCL-XL, thus identifying an effective therapeutic option for CML patients with high expression levels of CIP2A (Figure 7). The gene discussed is BCL2L1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.